Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

NCT04054193 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: Fosaprepitant Dimeglumine
DRUG: 5-HT3 antagonist
DRUG: Dexamethasone

Sponsor

Merck Sharp & Dohme LLC